Orforglipron

Orforglipron (LY-3502970; OWL-833) is an investigational small-molecule, non-peptide GLP-1 receptor partial agonist developed by Eli Lilly as a once-daily oral tablet for type 2 diabetes and obesity. It activates the GLP-1 receptor signaling pathway (cAMP) without the food/water restrictions of oral semaglutide, and has shown superior HbA1c reduction and weight loss versus oral semaglutide in Phase 3 head-to-head trials. Lilly has filed for global regulatory approval for weight management.